Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "Safety"

1765 News Found

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
Drug Approval | January 21, 2026

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells


Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India
News | January 21, 2026

Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India

The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures


AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
Clinical Trials | January 20, 2026

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial

Improvements were also seen in complete response rates, duration of response, and time to next treatment


Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
News | January 17, 2026

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy


EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
News | January 17, 2026

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike


Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
Clinical Trials | January 17, 2026

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer


AVEO Oncology doses first patient in pioneering AML clinical trial
Clinical Trials | January 16, 2026

AVEO Oncology doses first patient in pioneering AML clinical trial

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy


Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment
News | January 16, 2026

Sun Pharma launches Unloxcyt for advanced cutaneous squamous cell carcinoma treatment

UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation


Vetter advances next-gen syringe closure system towards 2027 launch
Medical Device | January 16, 2026

Vetter advances next-gen syringe closure system towards 2027 launch

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats


EMA and FDA unveil joint AI principles to transform drug revelopment
R&D | January 16, 2026

EMA and FDA unveil joint AI principles to transform drug revelopment

Experts caution that realizing AI’s potential requires careful management and risk mitigation